Barbara J Brandhuber

USPTO Granted Patents = 31 (Patent Applications = 4)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 69(Granted Patents)

Location History:

Golden, CO (US) (2006 - 2021)
Boulder, CO (US) (2017 - 2024)

Company Filing History:

Eli Lilly and Company

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12268666 - Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide (2025-04-08),

2. 12109193 - Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide (2024-10-08),

3. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

4. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

5. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),

6. 10907215 - Point mutations in TRK inhibitor-resistant cancer and methods relating to the same (2021-02-02),

7. 10889589 - Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain (2021-01-12),

8. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),

9. 10851080 - Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds (2020-12-01),

10. 10724102 - Point mutations in TRK inhibitor-resistant cancer and methods relating to the same (2020-07-28),

11. 10655186 - Point mutations in TRK inhibitor-resistant cancer and methods relating to the same (2020-05-19),

12. 10555944 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2020-02-11),

13. 10441581 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-10-15),

14. 10378068 - Point mutations in TRK inhibitor-resistant cancer and methods relating to the same (2019-08-13),

15. 10370727 - Point mutations in TRK inhibitor-resistant cancer and methods relating to the same (2019-08-06),

Title: Barbara J. Brandhuber: Innovator in Pharmaceutical Research and Development

Introduction: Barbara J. Brandhuber is a pioneering inventor based in Boulder, Colorado, recognized for her significant contributions to pharmaceutical innovations. With an impressive portfolio of 30 patents, her work continues to impact the treatment of critical diseases, particularly in oncology and autoimmune disorders.

Latest Patents: Among her latest innovations, she holds patents related to spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide. These inventions include pharmaceutical compositions aimed at effectively treating cancer and autoimmune diseases. Additionally, her research in substituted pyrazolo[1,5-a]pyridine compounds provides valuable RET kinase inhibitors for the treatment and prevention of RET-associated diseases.

Career Highlights: Barbara has significantly shaped the pharmaceutical landscape through her tenure at leading biopharmaceutical companies such as Array Biopharma Inc. and Loxo Oncology, Inc. Her dedication to innovation has consistently led to advancements in drug formulations and treatments.

Collaborations: Throughout her career, Barbara has collaborated with notable professionals, including Gabrielle R. Kolakowski and James F. Blake. These partnerships have fostered a creative environment for developing transformative healthcare solutions.

Conclusion: Barbara J. Brandhuber exemplifies the spirit of innovation in the pharmaceutical industry, driving forward the development of treatments that address some of the most pressing health challenges. Her extensive patent portfolio reflects her commitment to improving patient outcomes through groundbreaking research and collaboration.

This text is generated by artificial intelligence and may not be accurate.